Galectin Therapeutics Stock Price History
| GALT Stock | USD 1.59 0.06 3.92% |
Below is the normalized historical share price chart for Galectin Therapeutics extending back to September 04, 2002. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Galectin Therapeutics stands at 1.59, as last reported on the 22nd of March, with the highest price reaching 1.59 and the lowest price hitting 1.46 during the day.
If you're considering investing in Galectin Stock, it is important to understand the factors that can impact its price. Galectin Therapeutics is extremely dangerous given 3 months investment horizon. Galectin Therapeutics holds Efficiency (Sharpe) Ratio of 0.19, which attests that the entity had a 0.19 % return per unit of risk over the last 3 months. We were able to break down and interpolate twenty-nine different technical indicators, which can help you to evaluate if expected returns of 1.13% are justified by taking the suggested risk. Use Galectin Therapeutics Market Risk Adjusted Performance of (0.15), risk adjusted performance of 0.0134, and Downside Deviation of 9.67 to evaluate company specific risk that cannot be diversified away.
At this time, Galectin Therapeutics' Common Stock Shares Outstanding is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 34.1 M in 2025, whereas Common Stock is likely to drop slightly above 39.3 K in 2025. . Price Earnings Ratio is likely to drop to -2.3 in 2025. Price Book Value Ratio is likely to gain to -1.81 in 2025. Galectin Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 9th of September 2002 | 200 Day MA 2.1552 | 50 Day MA 1.3916 | Beta 0.69 |
Galectin |
Sharpe Ratio = 0.1907
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | GALT | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.91 actual daily | 52 52% of assets are less volatile |
Expected Return
| 1.13 actual daily | 22 78% of assets have higher returns |
Risk-Adjusted Return
| 0.19 actual daily | 15 85% of assets perform better |
Based on monthly moving average Galectin Therapeutics is performing at about 15% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Galectin Therapeutics by adding it to a well-diversified portfolio.
Galectin Therapeutics Stock Price History Chart
There are several ways to analyze Galectin Stock price data. The simplest method is using a basic Galectin candlestick price chart, which shows Galectin Therapeutics price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | March 13, 2025 | 1.76 |
| Lowest Price | December 24, 2024 | 0.84 |
Galectin Therapeutics March 22, 2025 Stock Price Synopsis
Various analyses of Galectin Therapeutics' daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell Galectin Stock. It can be used to describe the percentage change in the price of Galectin Therapeutics from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of Galectin Stock.| Galectin Therapeutics Price Daily Balance Of Power | 0.46 | |
| Galectin Therapeutics Accumulation Distribution | 102,007 | |
| Galectin Therapeutics Price Action Indicator | 0.10 | |
| Galectin Therapeutics Price Rate Of Daily Change | 1.04 |
Galectin Therapeutics March 22, 2025 Stock Price Analysis
Galectin Stock Price History Data
The price series of Galectin Therapeutics for the period between Sun, Dec 22, 2024 and Sat, Mar 22, 2025 has a statistical range of 1.47 with a coefficient of variation of 21.23. Under current investment horizon, the daily prices are spread out with arithmetic mean of 1.41. The median price for the last 90 days is 1.31. The company completed 1:6 stock split on 23rd of March 2012.| Open | High | Low | Close | Volume | ||
| 03/21/2025 | 1.53 | 1.59 | 1.46 | 1.59 | 1,247,624 | |
| 03/20/2025 | 1.57 | 1.60 | 1.53 | 1.53 | 141,698 | |
| 03/19/2025 | 1.60 | 1.64 | 1.49 | 1.57 | 227,713 | |
| 03/18/2025 | 1.58 | 1.64 | 1.55 | 1.58 | 233,017 | |
| 03/17/2025 | 1.67 | 1.70 | 1.50 | 1.61 | 383,971 | |
| 03/14/2025 | 1.75 | 1.79 | 1.64 | 1.68 | 197,189 | |
| 03/13/2025 | 1.72 | 1.80 | 1.66 | 1.76 | 208,718 | |
| 03/12/2025 | 1.59 | 1.71 | 1.55 | 1.71 | 159,068 | |
| 03/11/2025 | 1.60 | 1.64 | 1.55 | 1.60 | 202,683 | |
| 03/10/2025 | 1.58 | 1.64 | 1.58 | 1.59 | 197,817 | |
| 03/07/2025 | 1.62 | 1.63 | 1.57 | 1.62 | 77,422 | |
| 03/06/2025 | 1.55 | 1.63 | 1.55 | 1.60 | 106,564 | |
| 03/05/2025 | 1.61 | 1.65 | 1.53 | 1.57 | 239,162 | |
| 03/04/2025 | 1.47 | 1.68 | 1.47 | 1.59 | 252,970 | |
| 03/03/2025 | 1.59 | 1.59 | 1.47 | 1.49 | 248,971 | |
| 02/28/2025 | 1.47 | 1.57 | 1.41 | 1.57 | 196,373 | |
| 02/27/2025 | 1.50 | 1.55 | 1.48 | 1.48 | 183,342 | |
| 02/26/2025 | 1.49 | 1.58 | 1.45 | 1.52 | 313,615 | |
| 02/25/2025 | 1.46 | 1.49 | 1.43 | 1.47 | 158,506 | |
| 02/24/2025 | 1.49 | 1.53 | 1.45 | 1.46 | 204,634 | |
| 02/21/2025 | 1.51 | 1.53 | 1.45 | 1.49 | 267,208 | |
| 02/20/2025 | 1.51 | 1.52 | 1.44 | 1.47 | 145,959 | |
| 02/19/2025 | 1.55 | 1.60 | 1.45 | 1.52 | 271,171 | |
| 02/18/2025 | 1.51 | 1.63 | 1.45 | 1.53 | 718,430 | |
| 02/14/2025 | 1.30 | 1.54 | 1.30 | 1.41 | 517,904 | |
| 02/13/2025 | 1.30 | 1.32 | 1.30 | 1.30 | 150,992 | |
| 02/12/2025 | 1.30 | 1.33 | 1.25 | 1.31 | 132,004 | |
| 02/11/2025 | 1.30 | 1.31 | 1.27 | 1.31 | 112,262 | |
| 02/10/2025 | 1.30 | 1.33 | 1.23 | 1.30 | 434,027 | |
| 02/07/2025 | 1.32 | 1.34 | 1.27 | 1.31 | 279,185 | |
| 02/06/2025 | 1.30 | 1.33 | 1.24 | 1.32 | 487,316 | |
| 02/05/2025 | 1.25 | 1.30 | 1.22 | 1.30 | 216,031 | |
| 02/04/2025 | 1.26 | 1.26 | 1.22 | 1.25 | 160,073 | |
| 02/03/2025 | 1.23 | 1.26 | 1.19 | 1.23 | 261,255 | |
| 01/31/2025 | 1.26 | 1.28 | 1.23 | 1.25 | 239,117 | |
| 01/30/2025 | 1.22 | 1.27 | 1.22 | 1.25 | 229,518 | |
| 01/29/2025 | 1.24 | 1.25 | 1.20 | 1.23 | 145,490 | |
| 01/28/2025 | 1.22 | 1.25 | 1.19 | 1.23 | 144,828 | |
| 01/27/2025 | 1.22 | 1.24 | 1.20 | 1.22 | 240,389 | |
| 01/24/2025 | 1.23 | 1.28 | 1.20 | 1.22 | 142,775 | |
| 01/23/2025 | 1.21 | 1.27 | 1.19 | 1.23 | 265,052 | |
| 01/22/2025 | 1.21 | 1.23 | 1.18 | 1.21 | 186,456 | |
| 01/21/2025 | 1.24 | 1.24 | 1.11 | 1.23 | 696,373 | |
| 01/17/2025 | 1.25 | 1.29 | 1.21 | 1.24 | 229,512 | |
| 01/16/2025 | 1.25 | 1.29 | 1.24 | 1.25 | 172,392 | |
| 01/15/2025 | 1.20 | 1.29 | 1.17 | 1.28 | 312,913 | |
| 01/14/2025 | 1.09 | 1.16 | 1.07 | 1.15 | 261,316 | |
| 01/13/2025 | 1.10 | 1.12 | 1.07 | 1.11 | 326,050 | |
| 01/10/2025 | 1.15 | 1.19 | 1.07 | 1.10 | 467,486 | |
| 01/08/2025 | 1.20 | 1.20 | 1.13 | 1.13 | 463,874 | |
| 01/07/2025 | 1.20 | 1.26 | 1.20 | 1.20 | 380,429 | |
| 01/06/2025 | 1.20 | 1.29 | 1.17 | 1.19 | 602,368 | |
| 01/03/2025 | 1.16 | 1.23 | 1.14 | 1.16 | 517,110 | |
| 01/02/2025 | 1.31 | 1.39 | 1.17 | 1.17 | 947,621 | |
| 12/31/2024 | 1.13 | 1.33 | 1.13 | 1.29 | 1,114,145 | |
| 12/30/2024 | 1.06 | 1.24 | 0.94 | 1.10 | 892,329 | |
| 12/27/2024 | 0.90 | 1.47 | 0.90 | 1.15 | 5,984,373 | |
| 12/26/2024 | 0.84 | 0.94 | 0.84 | 0.87 | 1,039,712 | |
| 12/24/2024 | 0.88 | 0.88 | 0.76 | 0.84 | 1,700,806 | |
| 12/23/2024 | 0.92 | 0.92 | 0.85 | 0.89 | 2,794,447 | |
| 12/20/2024 | 1.18 | 1.50 | 0.73 | 1.04 | 9,268,164 |
About Galectin Therapeutics Stock history
Galectin Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Galectin is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Galectin Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Galectin Therapeutics stock prices may prove useful in developing a viable investing in Galectin Therapeutics
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 69.2 M | 72.6 M | |
| Net Loss | -35 M | -36.7 M |
Galectin Therapeutics Quarterly Net Working Capital |
|
Galectin Therapeutics Stock Technical Analysis
Galectin Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Premium Stories Now
Premium StoriesFollow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope |
| All Next | Launch Module |
Galectin Therapeutics Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for Galectin Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Galectin Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Galectin to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0134 | |||
| Jensen Alpha | 0.0181 | |||
| Total Risk Alpha | 0.7371 | |||
| Sortino Ratio | 0.0109 | |||
| Treynor Ratio | (0.16) |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Additional Tools for Galectin Stock Analysis
When running Galectin Therapeutics' price analysis, check to measure Galectin Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Galectin Therapeutics is operating at the current time. Most of Galectin Therapeutics' value examination focuses on studying past and present price action to predict the probability of Galectin Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Galectin Therapeutics' price. Additionally, you may evaluate how the addition of Galectin Therapeutics to your portfolios can decrease your overall portfolio volatility.